SCHEMBL4018879

SCHEMBL4018879

Cc1c2c(=O)[nH]c3cc4c(cc3c2nn1Cc1ccccc1)CCCC4

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.51
ADORA3 P0DMS8 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
KMT2A Q03164 5/20 0.38
HSD17B10 Q99714 2/20 0.38
KIF11 P52732 1/20 0.38
KDM4E B2RXH2 4/20 0.38
PKM P14618 1/20 0.38
MEN1 O00255 4/20 0.37
HPGD P15428 2/20 0.37
PSMD14 O00487 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
TYMS P04818 2/20 0.37
POLB P06746 1/20 0.37
PARP1 P09874 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128346 0.73 CHEK1 (0.41) CHEK1KMT2AKDM4EMEN1PTGDR2
SCHEMBL5129229 0.72 CHEK1 (0.50) CHEK1KIF11PARP1
SCHEMBL14192082 0.70 PDE4A (0.35) CHEK1KMT2AKDM4EMEN1TSHR
SCHEMBL4017149 0.68 CHEK1 (1.00) CHEK1KIF11
SCHEMBL14192084 0.68 PRMT5 (0.34) CHEK1KMT2AHSD17B10KDM4EMEN1
SCHEMBL14192083 0.67 GAA (0.33)
SCHEMBL5533986 0.64 PARP1 (0.65) HTR2CHTR2BKMT2AHSD17B10KDM4E
SCHEMBL31194533 0.61 PDE5A (0.47) KMT2AHSD17B10KDM4EMEN1HPGD
SCHEMBL7833852 0.60 HPGD (0.53) KMT2AKDM4EMEN1HPGDPSMD14
SCHEMBL23334344 0.60 PDE4A (0.60) HTR2CHTR2BKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7550477-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
US-20090023767-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2009-01-22 US disclosed
EP-1976523-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2008-10-08 EP disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
EP-1835918-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-09-26 EP disclosed
WO-2007081572-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-07-19 WO disclosed
WO-2007081572-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2007-07-19 WO disclosed
WO-2006074281-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114016-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885ADORA3 2484/4885HTR2C 4608/4885
US-20090023767-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885ADORA3 3769/4885HTR2C 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.